Please assess the completion status of the following clinical trial:

Trial Title: Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* At least 18 years of age~* Subject needed elective cardiac surgery with cardiopulmonary bypass except for heart transplantation~* Subject had a baseline ATIII level of less than 100% and equal to or above 60%~* Subject signed the informed consent form~* Subject was willing to comply with all aspects of the protocol, including blood sampling, for the total duration of the study~Exclusion Criteria:~* Documented congenital ATIII deficiency or ATIII levels below 60%~* Subject had a baseline ATIII level of 100% or higher~* Subject needed emergency (non-elective) surgery~* Subject needed heart transplantation~* History of anaphylactic reaction(s) to blood or blood components~* Allergies to excipients~* Subject was pregnant~* Subject had any medical condition that according to the investigators judgment worsens the surgical outcome above the expected~* Subject had any medical condition which is likely to interfere with the evaluation of the study treatment and/or the satisfactory conduct of the trial according to the investigators judgment~* Subject had participated in any another investigational study within the last 30 days previous to the inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Antithrombin III treatment group (Type: EXPERIMENTAL): Preoperative ATIII supplementation administered immediately after anesthesia induction
- Control group (Type: NO_INTERVENTION): No preoperative ATIII supplementation administered

Based on this trial design, predict the completion outcome and termination type (if applicable).